HC Wainwright Predicts Reduced Earnings for SOPHiA GENETICS

SOPHiA GENETICS SA (NASDAQ:SOPH) – Equities researchers at HC Wainwright reduced their FY2029 earnings per share estimates for SOPHiA GENETICS in a research note issued on Wednesday, August 5th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $0.31 per share for the year, down from their prior forecast of $0.34. HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for SOPHiA GENETICS’s current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for SOPHiA GENETICS’s FY2030 earnings at $0.72 EPS.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. BTIG Research lifted their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $10.00.

SOPHiA GENETICS Stock Performance

Shares of SOPH opened at $6.30 on Thursday. The company has a 50-day moving average of $5.54 and a two-hundred day moving average of $5.12. The stock has a market cap of $528.51 million, a price-to-earnings ratio of -5.48 and a beta of 0.96. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. SOPHiA GENETICS has a one year low of $2.96 and a one year high of $7.21.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 153.15%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Perkins Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter worth about $49,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS in the third quarter valued at approximately $49,000. First Dallas Securities Inc. bought a new stake in SOPHiA GENETICS in the first quarter worth approximately $50,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS during the 4th quarter valued at $54,000. Finally, XTX Topco Ltd bought a new stake in SOPHiA GENETICS in the fourth quarter worth $55,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Insider Activity

In related news, insider Zhenyu Xu sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $6.92, for a total transaction of $69,200.00. Following the transaction, the insider directly owned 600,887 shares of the company’s stock, valued at approximately $4,158,138.04. The trade was a 1.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jurgi Camblong sold 50,069 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20. Following the completion of the sale, the chief executive officer owned 3,601,493 shares of the company’s stock, valued at approximately $20,888,659.40. The trade was a 1.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 256,092 shares of company stock worth $1,492,420 in the last 90 days. Company insiders own 4.88% of the company’s stock.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: SOPHiA GENETICS raised its fiscal 2026 revenue outlook to $94 million–$96 million, above the roughly $93.4 million analyst consensus. Management continues to target adjusted EBITDA breakeven by year-end, which could improve confidence in the company’s path toward profitability. 2026 revenue outlook article
• Positive Sentiment: The company entered a multi-year collaboration with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The agreement may expand SOPH’s customer base and create longer-term opportunities in oncology testing. AstraZeneca partnership article
• Positive Sentiment: HC Wainwright raised its price target from $12 to $14 and BTIG Research increased its target from $8 to $9; both firms maintained Buy ratings. These revisions suggest some analysts see substantial upside if SOPH delivers on its growth and profitability targets. Analyst price target updates
• Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu collectively sold 35,000 shares worth approximately $242,350. Because all three transactions were conducted under pre-arranged Rule 10b5-1 plans and represented relatively small reductions in ownership, the sales provide limited information about management’s current outlook.
• Negative Sentiment: SOPH reported a quarterly loss of $0.26 per share, worse than the $0.21 loss analysts expected. Although revenue of $23.31 million exceeded the $21.72 million consensus, the company remains deeply unprofitable, with a negative net margin and analysts projecting a full-year loss. The earnings miss likely contributed to selling pressure. Q2 2026 earnings call transcript

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.